Tag: BPH
Cook Medical announces investment in Zenflow urinary obstruction device
Cook Medical has announced a strategic investment in the urology space via Zenflow, a medical device company developing a minimally invasive treatment for urinary...
Study shows long-term viability of PAE in treating benign prostatic hyperplasia
A single-centre report of mid- to long-term outcomes following prostate artery embolization (PAE) in a large cohort has found that the treatment shows significant...
SIR and Congressional Men’s Health Caucus collaborate on PAE briefing
On 5 June, the Society of Interventional Radiology (SIR) held a briefing in Washington DC, USA, of which the focus was benign prostate hyperplasia...
Registry reinforces safety, efficacy and efficiency of radial access in visceral...
The final results of the RAVI prospective registry study demonstrated the safety and efficacy of radial access in visceral interventions in standard embolization procedures...
Study finds PAE “highly effective” long-term treatment for enlarged prostate
Prostate artery embolization (PAE) provides long-term effectiveness in treating urinary symptoms from an enlarged prostate gland, according to new research to be presented at...
Interventional News’ top 10 most popular stories of January 2023
Interventional News’ most popular stories in the opening month of 2023 included news of first enrolments in clinical studies of peripheral arterial disease (PAD)...
Interventional News Issue 87—September 2022 US Edition
Interventional News 87 Highlights:
Ten-year data on PAE for benign prostatic hyperplasia
The success of interventional radiology outpatient clinics
Profile: Alban Denys
Diversity in...
Interventional News Issue 87—September 2022 Edition
Interventional News 87 Highlights:
Ten-year data on PAE for benign prostatic hyperplasia
The success of interventional radiology outpatient clinics
IR awareness: an initiative run...
Teleflex announces collaboration with FundamentalVR to improve training through virtual reality...
Teleflex has announced a new agreement with FundamentalVR, a company providing virtual reality (VR) integration for medical simulation. The agreement will provide Teleflex with...
Top 10 most popular Interventional News items of July 2022
Prostate conditions and their treatment proved popular reading topics during the month of July. Interventional News reported on this subject from various angles—from an...
Embolx files 510(k) for new Soldier high-flow microcatheter
Embolx, a medical device company developing microcatheters for arterial embolization procedures to treat cancerous tumours, benign prostatic hyperplasia, and uterine fibroids, has announced that...
“Promising” 10-year findings on PAE for BPH presented at ET 2022
Tiago Bilhim (Saint Louis Hospital, Lisbon, Portugal) presented during the Scientific Paper session at this year’s European Conference on Embolotherapy (22–25 June, Nice, France),...
New data reinforce efficacy of the UroLift system for the treatment...
Teleflex has announced the results of several research studies that further support the safety and efficacy of the UroLift system for men living with...
Teleflex granted reimbursement approval for the “UroLift System” in Japan
Teleflex Incorporated have announced that the company has received reimbursement approval from the Central Social Insurance Medical Council of Japan (Chuikyo) for the UroLift...
One-year snapshot shows cost benefits for prostate artery embolization over gold...
Prostate artery embolization (PAE) is more cost-effective than transurethral resection of the prostate (TURP), the gold standard for the management of patients with benign...
12-month data show UroLift system a good treatment option for men...
Twelve-month data from the multicentre prospective MedLift study of the Urolift system (NeoTract, a Teleflex subsidiary) for benign prostatic hyperplasia (BPH) involving a median...
Real-time imaging: Ultrasound detects a biodegradable embolic microsphere after prostatic artery...
Researchers report the use of ultrasound to detect embolization in real time for patients undergoing treatment for benign prostatic hyperplasia (BPH). Richard Owen (University...
Prostatic artery embolization improves BPH symptoms nearly as much as TURP...
A randomised, open label trial that was published in the BMJ on 19 June 2018 suggests that the improvement in lower urinary tract symptoms...
Multicentre UK registry results highlight embolization strengths and importance of physician...
First results from the UK-ROPE multicentre registry reveal that prostatic artery embolization is highly effective in reducing lower urinary tract symptoms in men with benign prostatic obstruction.
Randomised trial finds prostatic artery embolization “a real treatment alternative” to...
Six-month results from a prospective, randomised, non-inferiority study presented at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE; 16–20 September, Copenhagen, Denmark) reveal...
Teleflex completes acquisition of UroLift creator, NeoTract
Teleflex has announced the completion of its previously announced acquisition of NeoTract.
Founded in 2004, NeoTract is a privately-held medical device company that has developed...
Embosphere receives US FDA de novo classification for prostatic artery embolization
Merit Medical has announced that it has received 513(f)(2) (de novo) classification from the FDA to expand indication for its Embosphere microspheres. The indication...
High radiation dose to operator with prostatic artery embolization, until imaging...
According to our results, the physician who performs prostatic artery embolization procedures, even with a ceiling suspended shield, would reach the annual radiation limit...
Study suggests adenomatous-dominant benign prostatic hyperplasia could predict successful embolization
A study recently published in Cardiovascular and Interventional Radiology has, for the first time, identified adenomatous-dominant benign prostatic hyperplasia as a predictor of clinical...
1,000-patient study indicates prostate artery embolization remains effective for years
Prostate artery embolization maintains its effectiveness for at least three years after patients undergo the therapy, according to research presented at the Society of...
